Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar

INTRODUCTION: TNF-α-neutralizing antibodies, such as infliximab (IFX) and adalimumab (ADA), are effective in the treatment of inflammatory bowel diseases (IBD), but they are expensive and become ineffective when patients develop anti-IFX or anti-ADA antibodies (ATI and ATA, respectively). Second-gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Buurman, D. J., Blokzijl, T., Festen, E. A. M., Pham, B. T., Faber, K. N., Brouwer, E., Dijkstra, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289430/
https://www.ncbi.nlm.nih.gov/pubmed/30533022
http://dx.doi.org/10.1371/journal.pone.0208922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289430/
https://www.ncbi.nlm.nih.gov/pubmed/30533022
http://dx.doi.org/10.1371/journal.pone.0208922

Ejemplares similares